PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 65 | 4 | 58–62
Article title

Tumor Necrosis Factor-related apoptosis inducing ligand (TRAIL) and its receptors

Content
Title variants
PL
Ligand czynnika martwicy nowotworu (TRAIL) i jego receptory
Languages of publication
EN
Abstracts
EN
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a cytokine of the tumor necrosis factor (TNF) superfamily. The mRNA for TRAIL is expressed in most of the normal human cells and tissues, including T cells, monocytes, macrophages, dentritic cells, natural killer cells (NK) and spleen, lung, prostate. The most important biological function of this cytokine is inducing apoptosis in cancer, transformed cells with little or no cytotoxity against non-transformed cells and tissues and thus TRAIL is promising anticancer cytokine. TRAIL induces programmed cell death through interacting with its receptors. Five TRAIL receptors have been identifi ed: TRAIL-R1 and TRAIL-R2 have ability to initiate the apoptosis- signaling cascade after ligation, whereas “decoy receptors”-TRAILR3, -R4 and osteoprotegerin (OPG) lack this ability. TRAIL induces apoptosis in several tumor cell lines, but many primary tumors are resistant to TRAIL-induced apoptosis. Several mechanisms underlying TRAIL resistance have been proposed. Thus, scientists are currently attempting to identity TRAIL sensitizers that are able to overcome TRAIL resistance in cancer cells. The chemotherapy agents, radiation, lipopolysaccharide, interferons, fl avonoids are capable of enhancing TRAIL-induced apoptosis in cancer cells.
PL
Ligand czynnika martwicy nowotworu (TRAIL) jest cytokiną należącą do nadrodziny czynnika martwicy nowotworów (TNF). Ekspresję mRNA dla TRAIL stwierdzono w wielu prawidłowych komórkach i tkankach organizmu: limfocytach T, monocytach, makrofagach, komórkach dendrytycznych, komórkach natural killer (NK), a także w śledzionie, płucach, gruczole krokowym. Najważniejszą funkcją biologiczną tej cytokiny jest indukowanie apoptozy w komórkach nowotworowych, transformowanych,bez działania cytotoksycznego w stosunku do niezmienionych komórek i tkanek, dlatego TRAIL jest obiecujacą cytokiną antynowotworową. TRAIL indukuje programowaną śmierć komórki poprzez interakcje ze swoimi receptorami. Zidentyfikowano pięć receptorów TRAIL: TRAIL-R1 i TRAIL-R2, mających zdolność inicjowania sygnału do apoptozy po połączeniu z ligandem, oraz „receptory pułapki” – TRAIL-R3 i TRAIL-R4, osteoprotegeryna (OPG) – nieposiadające tej zdolności. TRAIL indukuje apoptozę wielu linii komórek nowotworowych, jednak wiele pierwotnych nowotworów jest opornych na apoptozę indukowaną TRAIL. Zaproponowano wiele mechanizmów leżących u podstaw tej oporności. Naukowcy starają się zidentyfikować czynniki uwrażliwiające komórki nowotworowe w celu przełamania ich oporności na TRAIL. Chemioterapia, promieniowanie, lipopolisacharyd, interferony, flawonoidy są zdolne usprawniania apoptozy indukowanej TRAIL w komórkach nowotworowych.
Discipline
Year
Volume
65
Issue
4
Pages
58–62
Physical description
References
  • 1. Wiley S.R., Schooley K., Smolak P.J. i wsp. Identifi cation and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 637–682.
  • 2. Holoch P.A., Griffi th T.S. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol. 2009; 625: 63–72.
  • 3. Thorburn A., Behbakht K., Ford H. TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them. Drug Resist. Updates. 2008; 11: 17–24.
  • 4. Griffi th T.S., Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanism. Curr. Opin. Immunol. 1997; 10: 559–663.
  • 5. Ehrlich S., Infante-Duarte C., Seeger B., Zipp F. Regulation of soluble and surface – bound TRAIL in human T cells, B cells and monocytes. Cytokine 2003; 24: 244–253.
  • 6. Cha S.S., Kim M.S., Choi Y.H. i wsp. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11: 253–261.
  • 7. Cha S.S., Sung B.J., Kim Y.A. i wsp. Crystal structure of TRAIL-DR5 complex idetifi es a critical role of the unique frame insertion in conferring recognition specifi ty. J. Biol. Chem. 2000; 275: 31171–31177.
  • 8. Seol D.W., Billiart T.R. Cysteine 230 modulates Tumor Necrosis Factor-related apoptosis- inducing ligand activity. Cancer Res. 2000; 60: 3152–3154.
  • 9. Kamohara H., Matsuyama W., Shimozato O. i wsp. Regulation of Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology 2004; 111: 186–194.
  • 10. Buchsbaum D.J., Forero-Torres A., LoBuglio A.F. TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol. 2007; 3: 405–409.
  • 11. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006; 17: 245–257.
  • 12. Sheikh M.S., Fornance Jr A.J. Death and decoy receptors and p53–mediated apoptosis. Leukemia 2000; 14: 1509–1513.
  • 13. Mantovani A., Locati M., Vecchi A., Sozzani S., Allavena P. Decoy receptors: a strategy to regulate infl ammatory cytokines and chemokines. Trends Immunol. 2001; 6: 328–336.
  • 14. Lünemann J.D., Waiczies S., Ehrlich S. i wsp. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specifi c T cells. J. Immunol. 2002; 168: 4881–4888.
  • 15. Kavurma M.M., Bennett M.R. Expression, regulation and function of TRAIL in atherosclerosis. Biochem. Pharmacol. 2008; 75: 1441–1450.
  • 16. Degli-Espositi M.A., Smolak P.J., Walczak H. i wsp. Cloning and characterization of TRAIL-R3, novel member of the emerging TRAIL receptor family. J. Exp. Med. 1997; 7: 1165–1170.
  • 17. Golstein P. Cell death: TRAIL and its receptors. Curr. Biol. 1997; 7: R745–R749.
  • 18. Mellier G., Huang G., Shenoy K., Pervaiz S. TRAILing death in cancer. Mol. Asp. Med. 2010; 31: 93–112.
  • 19. Mahalingam D., Szegezdi E., Keane M., de Jong S., Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat. Rev. 2009; 35: 280–288.
  • 20. Hernandez A., Wang Q.D., Schwartz S.A., Evers B.M. Sensitization of human colon cancer cells to TRAIL – mediated apoptosis. J. Gastrointest. Surg. 2001; 1: 56–65.
  • 21. Almasan A., Ashkenazi A. Apo2L/ TRAIL: apoptosis signaling, biology and potencial for cancer therapy. Cytokine Growth Factor Rev. 2003; 14: 337–348.
  • 22. Wu G.S. TRAIL as a target in anti-cancer therapy. Cancer Lett. 2009; 285: 1–5.
  • 23. Cuello M., Ettenberg S.A., Nau M.M., Lipkowitz S. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 2001; 81, 380–390.
  • 24. Stepulak A., Stryjecka-Zimmer M., Kupisz K., Polberg K. Histone deacetylase inhibitors as a new generation of anti-cancer agents. Postępy Hig. Med. Dośw. 2005; 59: 68–74.
  • 25. Koschny R., Walczak H., Ganten T.M. The promise of TRAIL – potential and risks of a novel anticancer therapy. J. Mol. Med. 2007; 85: 923–935.
  • 26. Maduro J.H. Targeting pro-apoptotic TRAIL receptors sensitizes HELA cervical cancer cells to irradiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 2008; 2: 543–553.
  • 27. Szliszka E., Czuba Z.P., Jernas K., Król W. Dietary fl avonoids sensitize Hela cells to Tumor necrosis factor-related apoptosis inducing ligand. Int. J. Mol. Sci. 2008; 1: 56–64.
  • 28. Oshima K. i wsp. Involvement of TRAIL/ TRAIL-R interaction in INF-􀄮 – induced apoptosis in Daudi B lymphoma cells. Cytokine 2001; 4: 193–201.
  • 29. Gomez-Benito M., Balsas B., Bosque A., Anel A., Marzo I., Naval J. Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-􀄮 in human myeloma cells. FEBS Letters 2005; 579: 6217–6222.
  • 30. Vogler M., Walczak H., Stadel D. i wsp. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009; 15: 2425–2434.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-5d96adfa-68cd-44eb-bcaa-e2e4c603af2c
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.